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Purpose: Multiparametric magnetic resonance imaging (mpMRI) is an emerging technique aiming to
improve upon the diagnostic sensitivity of prostate biopsy. Because of variance in interpretation and
application of techniques, results may vary. There is likely a learning curve to establish consistent
reporting of mpMRI. This study aims to review current literature supporting the diagnostic utility of
mpMRI when compared with radical prostatectomy (RP) and template transperineal biopsy (TTPB)
specimens.
Methods: MEDLINE and PubMed database searches were conducted identifying relevant literature
related to comparison of mpMRI with RP or TTPB histology.
Results: Data suggest that compared with RP and TTPB specimens, the sensitivity of mpMRI for prostate
cancer (PCa) detection is 80e90% and the speciﬁcity for suspicious lesions is between 50% and 90%.
Conclusions: mpMRI has an increasing role for PCa diagnosis, staging, and directing management to-
ward improving patient outcomes. Its sensitivity and speciﬁcity when compared with RP and TTPB
specimens are less than what some expect, possibly reﬂecting a learning curve for the technique of
mpMRI.
Copyright © 2015 Asian Paciﬁc Prostate Society, Published by Elsevier. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Prostate cancer (PCa) is the second most common cause of
cancer death in Australian men and is the most commonly diag-
nosed internal malignancy with one in seven Australian men being
diagnosed with PCa by the age of 75.1 PCa may ﬁrst present with
elevated prostate-speciﬁc antigen (PSA) on screening or symp-
tomatically with lower urinary tract symptoms, bony pain from
metastases or uncommonly with hematuria, urinary retention, or
renal failure.2 The deﬁnitive diagnosis of PCa is generally made by a
biopsy, typically transrectal ultrasound (TRUS)-guided biopsy.
Staging is typically by a nuclear medicine bone scan or computed
tomographyepositron emission tomography.3vel 8 Harold Stokes Building,
84, Australia.
rentschuk).
ciﬁc Prostate Society, Published bAn inﬂuential work by McNeal et al in 19884 demonstrated
trends in the zonal origin of PCa, particularly the predominance of
malignancy within the peripheral zone (PZ) and hence its amena-
bility to detection on digital rectal examination (DRE) and TRUS-
guided biopsy. However, a minority of cancers arose from more
anterior regions of the prostate leading to a newly articulated
phenomenon “prostatic evasive anterior tumor syndrome (PEATS).”
PEATS describes a subset of PCa which, due to anatomical location,
may be missed by traditional investigations such as DRE and TRUS
biopsy, both of which primarily focus on the PZ, but may be
detected bymultiparametric magnetic resonance imaging (mpMRI)
or transperineal biopsy (TPB).5
Management of PCa depends on risk stratiﬁcation, most
commonly the Gleason score, TNM staging, and PSA level. Lower risk
cancers may be indolent and require active surveillance (AS)
involving (with local variation) monitoring PSA levels (serial PSA
tests), DREs, biopsy, and possibly mpMRI or watchful waiting fory Elsevier. This is an open access article under the CC BY-NC-ND license (http://
Prostate Int 3 (2015) 107e114108patients deemed not suitable for active treatment with curative
intent by their treating clinician. Higher risk cancers may be treated
with radical prostatectomy (RP), external beam or interstitial
(brachytherapy) radiotherapy, androgen deprivation therapy, or a
combinationof these.Newer focal therapies are under investigation.3
This literature review aims to describe mpMRI and to explore
the evolving role for PCa diagnosis and staging.6 The sensitivity and
speciﬁcity of mpMRI reported in the literature is approximately
80e90% and 50e90%, respectively, when compared with RP and
template TPB (TTPB) specimens.2. Materials and methods
MEDLINE and PubMed database searches were conducted from
August 2014 to January 2015 using combinations of the MeSH
terms “prostate,” “prostatic neoplasia,” “diagnosis,” “magnetic
resonance imaging,” and using speciﬁc search terms such as
“mpMRI,” “multiparametric,” or “erMRI.”3. Discussion
Multiparametric MRI (mpMRI) is an emerging technique that
aims to improve upon the diagnostic sensitivity of prostate biopsy,
and ultimately reduce the number of biopsies performed and better
direct management decisions. The recently released 2014 National
Institute for Health and Care Excellence (NICE) guidelines for
management of PCa in the United Kingdom recommended an
increasing role for mpMRI based on clinical and cost effectiveness.
However, these guidelines recommended against utilizing mpMRI
before biopsy due to insufﬁcient cost beneﬁt.3 It is important to
distinguish multiphasic MRI from conventional 1.5-T MRI tech-
niques without dynamic contrast-enhanced MRI (DCE-MRI) or
diffusion-weighted imaging (DWI), which have been shown not to
be provide sufﬁciently reliable information for clinical decision
making.7 The sequences involved in mpMRI are detailed in Table 1.
Tables 2 and 3 summarize the literature regarding the diagnostic
utility of mpMRI for PCa.Table 1
Details of magnetic resonance sequences.
Magnetic resonance sequence Technical details
DWI/ADC The apparent diffusion coefﬁcien
tissue dictates Brownian motio
molecules within that tissue.15
within PCa may result from the
of ﬂuid containing ducts with t
glandular tissue.17
DCE Malignant tissue has increased p
and vascularity relative to norm
causing early enhancement and
the contrast agent.15
Magnetic resonance spectroscopy Magnetic resonance spectroscop
increasing (choline þ creatinin
ratios, which have been correla
Gleason score.23
T1WI Detects postbiopsy hemorrhage,
T2WI Delineates the zonal anatomy of t
characteristics include homoge
Note. From “The role of magnetic resonance imaging in the diagnosis andmanagement of
P. Stricker, USANZ, 2013, BJU Int, 112, p. 6e20; Also from “MRI for men undergoing
J. Trachtenberg, D. Leibovici, and N. Lawrentschuk, 2010, Nat Rev Urol, 7, p. 543e51.
ADC, apparent diffusion coefﬁcient; DCE, dynamic contrast enhanced; DWI, diffusion-w
netic resonance imaging; PCa, prostate cancer; PIRADS, Prostate imaging and reporting d
zone.3.1. MRI after a negative TRUS
The NICE guidelines recommended consideration of an MRI af-
ter negative TRUS biopsy to assess the requirement for an addi-
tional biopsy.3 This particularly relates to PEATS, because anterior
or apical tumors may be missed by TRUS biopsy but still be visible
on mpMRI.5,83.2. Active surveillance
mpMRI has an emerging role within AS for low-grade disease,
partly to minimize morbidity due to repeat biopsy.9,10 The Prostate
Cancer Research International: Active Surveillance (PRIAS)d
guideline and study for the expectant management of localized
prostate cancer with curative intent study is a multicenter, inter-
national, ongoing study that includes a subgroup of men under-
going mpMRI as part of their AS for low-risk PCa. The PRIAS
protocol includes an MRI 3 months after diagnosis, similar to the
NICE guidelines recommending mpMRI for all men commencing
AS.3 In addition, PRIAS includes yearly mpMRI and some targeted
biopsies. The number, size, and prostate imaging-reporting and
data system (PI-RADS) progression of visible lesions direct whether
targeted biopsy is undertaken and longitudinal information will be
collected regarding correlation of MRI with biopsy and RP speci-
mens. PRIAS is expected to conclude in 2021 and may dictate the
future role of mpMRI in AS.11,123.3. Preoperative staging
The NICE guidelines recommended mpMRI to investigate for
regional nodal disease and the extent of the primary tumor in men
with histologically proven PCa if the tumor growth affects man-
agement, such as in preoperative staging.3 Organ-conﬁned disease
enables an operative approach to spare the neurovascular bundle,
minimizing concerns regarding positive surgical margins, and
thereby reducing postoperative morbidity relating to erectile
dysfunction without increasing mortality risk.13 mpMRI has beenClinical implications
t (ADC) of a
n of water
Lower ADC
replacement
ightly packed
ADC negatively correlates with tumor
grade.18,19 DWI is more sensitive for tumors
of a higher grade, stage and volume.20
ermeability
al tissue
washout of
Higher tumor grades correlate with
proportionately earlier enhancement and
washout.21 DCE-MRI may reduce accuracy
within the TZ.21,22
y detects
e)/citrate
ted with
A large clinical trial suggested that magnetic
resonance spectroscopy provides little
additional information compared with
T2WI.23
Magnetic resonance spectroscopy may not be
included in mpMRI sequences16,24 and is
optional in the PIRADS scoring system.15
which confounds other sequences.25
he prostate and capsule, and helps elucidate extracapsular extension.15 Suspicious
nous areas of low signal with ill-deﬁned margins.15,26
prostate cancer,” by J. Thompson, N. Lawrentschuk, M. Frydenberg, L. Thompson, and
active surveillance or with rising PSA and negative biopsies,” O. Raz, M. Haider,
eighted imaging; mpMRI, multiparametric magnetic resonance imaging; MRI, mag-
ata system; T1WI, T1-weighted imaging; T2WI, T2-weighted imaging; TZ, transition
Table 2
mpMRI with RP reference standard.
Reference Thompson et al19 Chamie et al41 Junker et al23 Hoeks et al40 a) Delongchamps et al22 Yoshizako et al29 a) Villers et al43
Year 2014 2014 2014 2013 2011 2008 2006
Retrospective /prospective Prospective Retrospective Prospective Retrospective Retrospective Retrospective Prospective
Age (y) 62 61, mean 63, mean 67 63 65 63
Prostate-speciﬁc antigen 5.6 5.6, mean 7.3, mean 9 7 NR 9.9
Sensitivity (%) 98 96 97 65 78 69 77
Speciﬁcity (%) 43 46 79 67 97 94 91
Negative predictive value (%) 75 92 NR NR NR NR NR
Positive predictive value (%) 91 66 NR NR NR 95 NR
N 48 115 50 63 a) 57 35 a) 24
MRI sequence T2, DWI, DCE T2, DWI T2, DWI, DCE T2, DWI, DCE T2, DWI, DCE T2, DWI, DCE T2, DCE
Field strength (T) 1.5/3 alternating 3 3 3 1.5 1.5 1.5
Coil PPA ERC PPA ERC ERC PPA PPA
No. of readers, experience 2, 1,000þ prostate
MRI reported
1, Experienced 1, Experienced 4, 3e10 y 2, Experienced 2 y, 13 y, and 15 y 2 y, 15 y, and 4 y
Radiologist blinding NR Blinded to clinical Blinded to
clinical
PCa known,
not location
Blinded to
clinical
PCa known,
not location
Blinded to
biopsy and
histopathology
Time from MRI to RP NR NR 1 d NR NR 1e7 wk,
median 4
30 d, mean
Reporting system PI-RADS Epstein criteria or
ADC < 850 mm2/s
PI-RADS Likert Likert Likert Likert
Signiﬁcant cancer deﬁnition GS  7, GS¼ 6 CL  5 mm
or 20% cores positive b)
pT3, GS  4þ3,
GS¼ 3 þ 4 and  1.3 mL
Any PCa Any PCa Any PCa Any PCa Any PCa
Age and PSA are median values unless labeled as mean. PIRADS 3e5 was considered positive.
a) Only considers TZ PCa.
b) Paper reports other deﬁnitions.
ADC, apparent diffusion coefﬁcient; CL, core length; DCE, dynamic contrast enhanced; DWI, diffusion-weighted imaging; ERC, endorectal coil; GS, Gleason score; mpMRI, multiparametric magnetic resonance imaging; MRI,
magnetic resonance imaging; NR, not recorded; PCa, prostate cancer; PI-RADS, prostate imaging-reporting and data system; RP, radical prostatectomy; TZ, transition zone; UCL, University College London.
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Table 3
mpMRI with TPB reference standard.
Reference Pepe et al42 Thompson et al19 Grey et al34 Abd-Alazeez et al25 Abd-Alazeez et al32 Arumainayagam et al31
Year 2014 2014 2014 2014 2014 2013
Retrospective/prospective Prospective Prospective Prospective Retrospective Prospective Retrospective
Age (y) 65 62 65, mean 62 61 64, mean
Prostate-speciﬁc antigen 10.4 5.6 11.7, mean 5.8 10 8.2, mean
Sensitivity (%) 83 93 97 98, 94 90, 76 64e81, 58e73 a)
Speciﬁcity (%) 72 53 60 22,23 42,42 68e80, 71e83 a)
Negative predictive value (%) 88 52 98 98, 89 95, 79 91e94, 84e89 a)
Positive predictive value (%) 79 98 49, 58, 84 b) 21, 34 26, 38 35e45, 49e63 a)
N 168 150 201 129 54 64
N with prostate cancer 66 150 77 141 (two sectors) 34 54
MRI sequence T2, DWI, DCE, MRS T2, DWI, DCE T2w, DWI T2, DWI, DCE T2, DWI, DCE, T2, DWI, DCE
Field strength (T) 3 1.5/3 alternating 1.5 1.5 1.5 1.5
Coil PPA PPA PPA PPA PPA PPA
No of readers, experience 2, NR 2, 1,000þ prostate MRI reported 1, 4 y 5, 100 þ mpMRI/y 8, 3e8 y 3, 3e10 y
Radiologist blinding Blinded to clinical NR Blinded to clinical Blinded to biopsy Blinded to biopsy Blinded to biopsy
Time from MRI to TPB 3e10 d NR 43 d, median <1 y NR 106 d, median
Reporting system NR PI-RADS PI-RADS PI-RADS PI-RADS Likert
Number of cores 6-35, median 28 median 30, two targeted 24-40, two to four targeted 20e93, median 41 minimum 10e12 29e41, median 34
Prior negative biopsy Yes Mainly No Mixed No Yes Mixed
Signiﬁcant cancer deﬁnition NR GS  7, GS¼ 6 CL  5 mm
or 20% cores positive d)
GS  7, GS¼ 6 CL  6 mm UCL 1, UCL 2 c),d), and PIRADS 4 UCL 1, UCL 2 c) UCL 1, UCL 2 c)
a) Range is from different radiologists
b) PPV for PIRADS 3,4, and 5, respectively.
c) UCL 1: Gleason score of over 4 þ 3 and/or maximum cancer core length (CCLmax) of 6 mm or more; UCL 2: Gleason score of 3þ4 or more and/or CCLmax of 4 mm or more.33,36,37
d) Paper reports other deﬁnitions.
DCE, dynamic contrast enhanced; DWI, diffusion-weighted imaging; GS, Gleason score; mpMRI, multiparametric magnetic resonance imaging; MRI, magnetic resonance imaging; MRS, magnetic resonance spectroscopy; NR, not
recorded; PI-RADS, prostate imaging-reporting and data system; PPA, pelvic-phased array; TPB, transperineal biopsy; UCL, University College London.
Age and PSA are median values unless labeled as mean. PIRADS 3e5 was considered positive.
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Toner et al / Multiparametric MRI for prostate cancer 111shown to have a high positive predictive value (PPV) of around 90%
in a high-risk cohort and a negative predictive value (NPV) of
around 90% in a low-risk cohort for predicting extracapsular
extension versus organ-conﬁned disease.13e15 However, Billing
et al16 reported a PPV and NPV of approximately 70% in the general
case, which serves to remind that all MRI reports must be viewed in
their clinical context.
3.4. mpMRI sequences
A 2014 European Consensus Panel and the European Society for
Urogenital Radiology (ESUR) agreed that multiphasic MRI should
involve various submodalities such as T1-weighted images
(T1WIs), T2-weighted images (T2WIs), DWI and DCE as different
sequences provide an additive beneﬁt to accuracy.17,18 The role of
MR spectroscopy is less clear.18 The 2014 NICE guidelines only
recommend obtaining T2WI and DWI images and provide no rec-
ommendations regarding ﬁeld strength or the use of an endorectal
coil (ERC).3
3.5. Magnetic ﬁeld strength and ERCs
3-TMRImay be preferred due to increased spatial resolution and
signal-to-noise ratio.17,18 However, this may not improve diagnostic
accuracy.19,20 ERC, compared with a pelvic-phased array (PPA), may
be used to locally increase spatial resolution while also causing
signiﬁcant patient discomfort.7 Improvements in diagnostic accu-
racy are less clear.20 A 2014 International Consensus Panel recom-
mended the use of ERC at 1.5 T, but considered 3 T as optional; by
contrast, the ESUR considers them entirely optional.17,18
3.6. Scoring system for image interpretation
In 2012, the ESUR published a structured reporting system
known as the PI-RADS and recommendations on standardizing the
mpMRI protocol.17 The aim of these guidelines was to improve the
diagnostic accuracy of mpMRI for PCa, to improve communication
between radiologists, and to standardize the literature for better
comparisons between studies. A PI-RADS score has components
from different MRI sequences and an overall score from one to ﬁve,
with higher numbers reﬂecting an increasing probability of PCa risk
and aggression.17 Prior to these publications, many studies used
more subjective Likert scales, which have subsequently shown to
have greater interobserver variability.21
Some authors describe the PI-RADS system as awork in progress
due to ongoing controversy surrounding MRI protocols and the
deﬁnition and treatment of clinically signiﬁcant PCa.22e24 PI-RADS
3 is considered “equivocal” and it is unclear whether this should be
considered positive or not; in particular, the morbidity due to
overtreatment of PCa is a concern. The trend is that if equivocal
results are included, sensitivity is higher while speciﬁcity is lower.
Some authors report both and the difference in quantitative results
is substantial. For example, Abd-Alazeez et al25 reported, for Uni-
versity College London (UCL) deﬁnition 2, sensitivities of 94% and
68%with speciﬁcities of 23% and 69% for PI-RADS of 3 ormore and 4
or more, respectively.
Typically, it is local practice in Melbourne, Australia, for a radi-
ologist to recommend a biopsy of a PI-RADS 3 lesion. Fig. 1 illus-
trates the correlation between a PI-RADS 5 lesion identiﬁed on
mpMRI and an RP specimen.
3.7. Reference standard controversy
There is an ongoing controversy surrounding the reference
standard to which mpMRI is compared.26 Various authors advocatecomparing MRI with transrectal biopsy, TPB, or whole-mounted
prostatectomy specimens. Transrectal biopsies miss 20e30% of
clinically signiﬁcant tumors, typically caused by undersampling of
the apex, transition zone (TZ), and anterior horns of the PZ.2
Template-guided TPB provides a more comprehensive sample.27
RP whole-mount specimens minimize any sampling error, but
exacerbate selection error because menwith low-risk disease, who
are unﬁt for surgery, who choose alternative treatments, or those
without PCa are not sampled.26 By focusing on men with high-risk
PCa, this approach limits the investigation of the NPV and the role
for MRI to reduce unnecessary biopsies.19 Thompson et al19 used
TTPB and RP and reported similar results.
3.8. Benign disease mimicking carcinoma
Benign disease such as benign prostatic hyperplasia, biopsy
changes, ﬁbrosis, prostatitis, and prostatic intraepithelial neoplasia
can mimic the appearance of cancer on mpMRI.20 However, Junker
et al23 demonstrated that such mimics are almost exclusively
mistaken low-grade carcinoma as indicated by a PI-RADS score of 3
or less.
3.9. Timing of MRI postbiopsy
A 2014 European Consensus recommended that mpMRI should
be conducted at least 8 weeks after the biopsy to minimize the
confounding effect of postbiopsy hemorrhage.18 Hemorrhage can
cause decreased T2 signal potentially masking or mimicking tu-
mors and can involve areas quite distant from the needle trajec-
tory.28 However, a 2012 study by Rosenkrantz et al28 involving 44
patients showed that lengthy delay might not be necessary, as
hemorrhage can reliably be demonstrated on T1WI.
3.10. Deﬁnition of clinically signiﬁcant PCa
As mentioned earlier, PCa can range from indolent to lethal.
Appropriate risk stratiﬁcation is critical to guiding management, to
both reduce morbidity from overtreatment and mortality from
undertreatment. There is considerable variation in the deﬁnition of
“clinically signiﬁcant” PCa.9 For example, in 2008, Yoshizako et al29
included cancers with Gleason score 3 þ 3 and no size restrictions.
In 2011, Haffner et al30 deﬁned clinically signiﬁcant as either core
lengthof over 5mmorGleason score of 3þ 4 ormore. In 2015, Junker
et al23 deﬁned low grade as 3 þ 4 or less and high grade as 4 þ 3 or
more without mention of core length. In 2014, Abd-Alazeez et al25
reported results for ﬁve different deﬁnitions of clinical signiﬁcance
based around the Gleason score (either 4 þ 3 or 3 þ 4) and in-
dividual cancer core length (either 6 mm or 4 mm) or combina-
tions of the two. More recently, papers from UCL have attempted to
standardize reporting with the following deﬁnitions. UCL 1: Gleason
score of over 4 þ 3 and/or maximum cancer core length (CCLmax) of
6mmormore; UCL 2: Gleason score of 3þ4 ormore and/or CCLmax of
4 mm or more.25,31,32 More exclusive deﬁnitions of clinically signiﬁ-
cant PCa tend toward higher sensitivities compared with more in-
clusive deﬁnitions, with small decreases in speciﬁcities.
Arumainayagam et al31 and Abd-Alazeez et al25,32 compared the
more exclusiveUCL 1with themore inclusiveUCL 2, and showed that
sensitivity increases by 4e16% and speciﬁcity decreases by 0e3%.
Thompson et al19 analyzed four deﬁnitions and reported smaller
differences of 0e3% for both sensitivity and speciﬁcity.
3.11. Blinding
The studies in Tables 2 and 3 all used some form of blinding, but
the details varied. One would expect that a stricter blinding
Fig. 1. Prostate imaging-reporting and data system 5 lesion histologically proven to be prostate cancer. (A) Focal, irregular hypointensity on T2-weighted imaging, (B) focal restricted
diffusion on an apparent diffusion coefﬁcient map, and (C) correlation with radical prostatectomy (index lesion marked in yellow and other foci marked in black).
Prostate Int 3 (2015) 107e114112protocol results in less diagnostic accuracy, but this is not evident in
these tables so the effect is likely small.
3.12. Patient population and biopsy indication
By deﬁnition, sensitivity and speciﬁcity are independent of
disease prevalence, whereas PPV and NPV are not. Despite this, the
differing indications for mpMRI alter the diagnostic accuracy. For
example, Grey et al34 reported sensitivity varying from 85% to 100%
across primary biopsy, AS, and previous negative biopsy groups.
The effects were more pronounced for NPV varying from 27% to
77%.33,34 The two 2014 studies by Abd-Alazeez et al25,32 primarily
differ in the MRI indication as they are from the same institution
over similar periods. In the primary biopsy setting, with signiﬁcant
PCa deﬁned by UCL 2, sensitivity and speciﬁcity were reported as
94% and 23%, respectively, compared with 76% and 42% respectively
in the repeat biopsy setting. This variation may be accounted for by
the systematic differences between the groups in terms of tumor
size and location such as PEATS being more common in the pre-
vious negative biopsy group.5
3.13. Comment on speciﬁc papers
Tables 2 and 3 summarize the literature regarding the diagnostic
utility of mpMRI for PCa. They demonstrate the wide range of re-
sults and heterogeneity in terms of patient population, test indi-
cation, study design, MRI protocol, scoring system, radiologist
experience, biopsy protocol, signiﬁcant cancer deﬁnition, and
reference standard, all of which confound direct comparison.
Several papers were excluded as they only investigated the MRI
sequences individually and not their combined utility.35e37 A 2014
meta-analysis by de Rooij et al38 and a 2015 meta-analysis byFütterer et al39 were excluded as the relevant studies were already
included, and thus, the informationwas considered redundant. The
results of the meta-analyses largely agree with Tables 2 and 3 with
some differences as other reference standards such as TRUS biopsy
or MRI-guided biopsy were included.
The difﬁculty in imaging the TZ was illustrated by Hoeks et al40
as they reported disappointing results, with no signiﬁcant
improvement in mpMRI (including both DCE and DWIeMRI)
compared with T2WI MRI alone with accuracies of 66% and 68%,
respectively. These numbers are comparable to those obtained by a
smaller study Yoshizako et al29 where accuracy decreased from 83%
to 79% after DCE was added to T2WI and DWI for TZ PCa. Delong-
champs et al22 again showed the difﬁculty in imaging the TZ,
reporting a maximum sensitivity and speciﬁcity of 71% and 98% for
the TZ (results not statistically signiﬁcant), which is less favorable
than the PZ with 80% and 97%, respectively. This suggests that PCa
location is another confounding factor for comparing studies.
Delongchamps et al22 found that the addition of DCE to an
mpMRI protocol reduces accuracy within the TZ and reported
sensitivity and speciﬁcity of 53% and 83%, respectively, if DCE was
included; however, upon excluding DCE, they reported sensitivity
and speciﬁcity of 71% and 98%, respectively.22 This was supported
by Junker et al23 who reported a sensitivity and speciﬁcity within
the TZ as 53% and 83%, respectively, if DCE was included compared
with 71% and 98% if DCE was excluded.23 Junker et al23 subse-
quently recommended that the PI-RADS score developed in 2012 by
the ESUR be amended to reﬂect this ﬁnding.
Chamie et al41 demonstrated that the additional beneﬁt of DWI
in mpMRI is most signiﬁcant for higher grade disease, which is
particularly relevant as overtreatment of clinically insigniﬁcant
disease is a concern. Pepe et al42 also reported that the diameter of
lesions identiﬁed on mpMRI correlated with aggressiveness. Grey
Toner et al / Multiparametric MRI for prostate cancer 113et al34 reported that out of 88 patients with a negative MRI, only
two had low-volume Gleason score 3 þ 4 PCa on TPB (98% NPV). In
addition, Thompson et al19 suggested that avoiding biopsy of PI-
RADS 1 or 2MRI lesions may reduce unnecessary biopsies by 50% at
the cost of delaying diagnosis of Gleason score 3 þ 4 in 1% of pa-
tients. In both papers, no higher-grade disease was missed. This
suggests that MRI may have a role in reducing unnecessary biopsies
and associated morbidity.34
The two oldest studies by Villers et al43 and Yoshizako et al29
illustrated the evolution of mpMRI protocol across time. Villers
et al43 did not include DWI as their study preceded a number of
guidelines advocating its use.3,18,43 Further, both authors used a 1.5-
T ﬁeld strength without an ERC, which results in a lower spatial
resolution and is now perhaps thought to be insufﬁcient.18
Grey et al34 described a particular patientwhose PCawasmissed
bympMRI. The reference test (TPB) was performed 10 months after
the MRI (compared with the mean of 43 days) so it is possible the
cancer had either increased in volume or progressed in grade and
the original PI-RADS score of 1 or 2 may have been accurate at the
time.34 This case suggests that an additional confounding factor is
the time from MRI to biopsy and then to RP.
3.14. Interobserver variability and a learning curve
Interobserver variability and learning curves are likely contrib-
uting factors to the diversity of results in different studies of
mpMRI. The effects are greater when Likert scale scoring systems
are employed, as they rely heavily on the experience of senior ra-
diologists, and the effects are lessened for more well-deﬁned
scoring systems, such as PI-RADS. Gaziev et al44 demonstrated a
signiﬁcant learning curve for PCa detectionwith MRI reporting on a
Likert scale. The 2-year prospective study reported an increase in
cancer detection from 42% to 81%. Vache et al21 compared different
scoring systems for the diagnosis of PCa on mpMRI. Signiﬁcant
interobserver variability occurredwith the subjective Likert scoring
systemwith area under the curve (AUC) scores varying from 0.88 to
0.81. Interobserver variation was minimal across the more rigid
scoring systems as PI-RADS AUC varied from 0.75 to 0.76. Pokorny
et al,45 using PI-RADS, demonstrated no signiﬁcant difference in
accuracy between junior and senior radiologists and a urologist
after the protocol had been implemented for 18 months. Accuracy
did not increase with time across the 6-month study.
3.15. Future studies
The UCL Hospital is undertaking the Prostate Imaging Compared
to Transperineal Ultrasound Guided Biopsy for Signiﬁcant Prostate
Cancer Risk Evaluation (PICTURE) study and the multicenter
PROstate MRI Imaging Study: Evaluation of Multi-parametric
Magnetic Imaging in the Diagnosis and Characterisation of Pros-
tate Cancer (PROMIS) designed to prospectively assess the NPV of
mpMRI and the role to reduce biopsies.46 Both studies are expected
to be completed in 2014/2015.47
3.16. MR-guided biopsy
Lawrence et al48 electronically aligned and fused mpMRI images
with three-dimensional real-time TRUS imaging for targeted bi-
opsy. Pokorny et al45 described in-bore MR-guided prostate biopsy
reporting sensitivity and speciﬁcity of 92% and 97%, respectively, for
intermediate and high-grade PCa.45
In conclusion, mpMRI has an increasing role for PCa diagnosis,
staging, and directing management toward improving patient
outcomes. The sensitivity and speciﬁcity of mpMRI reported in the
literature is approximately 80e90% and 50e90% when comparedwith RP and TTPB specimens. This is less than what some expect,
possibly reﬂecting a learning curve for the technique of mpMRI.Conﬂicts of interest
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